642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p)

Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL)

A phase 3 randomized open label multicenter study of sonrotoclax BGB 11417 plus anti CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma CLL RR1 CELESTIAL RRCLL

Sonic Escalated inpatient ramp up of sonrotoclax in CLL SLL and MCL

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia small lymphocytic lymphoma – taza CLL

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

New chronic lymphocytic leukaemia therapies Does measurable residual disease testing accurately predict progression free survival

Initial treatment of chronic lymphocytic leukemia with low dose high frequency rituximab followed by addition of acalabrutinib

Continuous venetoclax for relapsed chronic lymphocytic leukemia CLL – characteristics and outcomes of long term responders

Ibrutinib plus rituximab leads to superior progression free and overall survival to FCR in previously untreated CLL Results of the Phase III NCRI FLAIR trial

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients A comprehensive retrospective analysis

Encouraging long term efficacy and safety from first in human phase 1 study of time limited NVG 111 in relapsed refractory CLL and MCL

A prospective single center single arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL SLL Stop Trial

Genetic and clinical profiles of chronic lymphocytic leukemia in Thailand Nationwide insights from the thai lymphoma study group

Comparative analysis of characteristics and outcomes in CD5 FMC7 lymphoproliferative disorders and classic CLL immunophenotype patients

Dissecting the heterogeneity of IGHV mutated CLL An eric study

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia small lymphocytic lymphoma Results from the dose escalation and confirmation segment of the Phase 3 bellwave 010 study

A post hoc safety analysis of fixed duration acalabrutinib venetoclax combinations vs chemoimmunotherapy Results from the phase 3 AMPLIFY trial

Venetoclax plus obinutuzumab improves quality of life in treatment naive CLL Prospective real world insights from the verve study

Retrospective evaluation of the G8 score in CLL patients treated with targeted therapies A single center experience

CLL with t 11 14 q13 q32 or t 14 18 q32 q21 –­­ is this CLL or lymphoma

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Long term event free survival in patients with IGHV mutated high count monoclonal B cell lymphocytosis and atypical non CLL like phenotypes

Real world RW treatment Tx patterns factors associated with discontinuation and toxicity across covalent BTK inhibitors cBTKis in first line 1L tx of chronic lymphocytic leukemia CLL and small lymphocytic lymphoma SLL

Outcomes of patients with Richter transformation RT treated with frontline chemoimmunotherapy CIT and BTK inhibitor BTKi

Impact of FMC7 expression on baseline characteristics and outcomes in CLL patients treated with upfront BTKi monotherapy

Venetoclax retreatment of real world patients with chronic lymphocytic leukemia previously treated with venetoclax based regimens

Redefining early vs late progressive disease PD in chronic lymphocytic leukemia A pooled analysis of fixed duration therapies